Protara Therapeutics Inc (TARA) Stock Analysis
Verdict: AVOID
Protara faces acute dilution risk with a 10.5-month cash runway before TARA-002 phase 2 data, making near-term equity raises likely.
Investment score: 33/100
Analysis as of
Is Protara Therapeutics Inc stock worth reviewing? The TradeMates thesis
The model evaluates Protara Therapeutics as an AVOID due to severe cash burn of -$56.46M annually against a cash balance of $49.66M, implying approximately 10.5 months of cash runway. Recent CEO stock sales of 215,687 shares at $4.09 and a 30.7% price drop over 90 days signal heightened equity dilution risk before commercial revenue materializes.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Protara Therapeutics Inc opportunities and risks
What speaks for TARA
- TARA-002 clinical milestone progression in Lymphatic Malformations and NMIBC
What speaks against TARA
- Imminent equity dilution due to 10.5-month cash runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TARA | n/a | 0.0x | n/a | 0.0% | 0.0% | -31.3% |
| AVXL | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.0% |
| ELDN | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.6% |
| PLX | 11.2x | 2.7x | 7.6x | 69.2% | 23.5% | 3.5% |
| ALEC | n/a | 15.5x | n/a | -360.9% | -850.1% | -73.5% |
| KROS | n/a | 23.2x | n/a | 94.7% | -553.9% | -13.9% |
| Peer median | n/a | 2.7x | n/a | 0.0% | 0.0% | -15.0% |
Frequently asked questions about Protara Therapeutics Inc (TARA)
Is TARA stock a good investment?
The TradeMates model rates Protara Therapeutics Inc as AVOID with an investment score of 33/100. The model evaluates Protara Therapeutics as an AVOID due to severe cash burn of -$56.46M annually against a cash balance of $49.66M, implying approximately 10.5 months of cash runway. Recent CEO stock sales of 215,687 shares at $4.09 and a 30.7% price drop over 90 days signal heightened equity dilution risk before commercial revenue materializes. This is algorithmic model output, not personal investment advice.
Is TARA stock a buy?
The TradeMates model verdict for TARA is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.